Tuesday, October 19, 2021 10/19/2021

On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49

Award Number: R01CA163764
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Pancreatic cancer is a devastating disease that is refractory to standard chemotherapies, as demonstrated by the low five-year survival rate of 8%. The objective of this proposal is to assess a novel, highly promising therapeutic for the treatment of pancreatic cancer, employing comprehensive in vitro and preclinical in vivo testing prior to clinical evaluation studies. The sigma-2 (S2) receptor is overexpressed in pancreatic cancer, and small molecule ligands to this receptor localize to these tumors. In addition, PDAC cancer cells rapidly internalize selected sigma-2 ligands. This finding prompted us to explore the possibility of using these ligands to deliver additional therapeutic payloads to PDAC tumor cells via chemical linkage with our ligands. We have successfully used S2 ligands to deliver structurally diverse compounds including both peptides and small molecule therapeutics (classic chemotherapeutics [rapamycin] and peptidomimetics), into the cancer cells both in vitro and in vivo. In each case, the activity profiles of the conjugates were far greater than the isolated components or their equimolar combinations. Based on this delivery concept, we combined the tumor selectivity of the S2 ligand SV119 with a promising drug cargo that induces cell death selectively in PDAC (dm-Erastin), by creating a single small molecule conjugate (SW V-49). We have shown that this conjugate efficiently kills tumor cells in stroma-rich pancreatic cancer models with only limited signs of systemic toxicity. The key tasks of this project involve pharmacology and toxicity drug testing employing PDAC cell lines in vitro (murine and human), primary patient-derived 3D organoid in vitro cultures as well as syngeneic (mouse) and patient-derived xenograft models (PDX) of pancreatic cancer.


Issue Date FY	Funding FY	Recipient Name	DUNS Number	City	State	CFDA Number	CFDA Program Title	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $381,250 )
2021	2021	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	10	3/19/2021	NON-COMPETING CONTINUATION	$381,250


Issue Date FY: 2020 ( Subtotal = $381,250 )
2020	2020	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	9	3/4/2020	NON-COMPETING CONTINUATION	$381,250


Issue Date FY: 2019 ( Subtotal = $369,812 )
2019	2019	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	8	3/25/2019	NON-COMPETING CONTINUATION	$369,812


Issue Date FY: 2018 ( Subtotal = $381,250 )
2018	2018	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	002	7	3/27/2018	NON-COMPETING CONTINUATION	$343,125
2018	2018	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	003	7	5/23/2018	NON-COMPETING CONTINUATION	$38,125
2018	2017	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	001	6	11/8/2017	COMPETING CONTINUATION	$2,470
2018	2016	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	5	11/8/2017	EXTENSION WITH OR WITHOUT FUNDS	-$2,470


Issue Date FY: 2017 ( Subtotal = $381,250 )
2017	2017	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	6	1/30/2017	COMPETING CONTINUATION	$381,250
2017	2017	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	002	6	8/16/2017	COMPETING CONTINUATION	$100,231
2017	2016	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	001	5	8/16/2017	EXTENSION WITH OR WITHOUT FUNDS	-$100,231


Issue Date FY: 2016 ( Subtotal = $371,287 )
2016	2016	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	5	3/31/2016	EXTENSION WITH OR WITHOUT FUNDS	$371,287


Issue Date FY: 2015 ( Subtotal = $371,287 )
2015	2015	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	4	3/13/2015	NON-COMPETING CONTINUATION	$371,287


Issue Date FY: 2014 ( Subtotal = $360,148 )
2014	2014	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	3	6/25/2014	NON-COMPETING CONTINUATION	$360,148


Issue Date FY: 2013 ( Subtotal = $337,151 )
2013	2013	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	2	3/4/2013	NON-COMPETING CONTINUATION	$161,402
2013	2013	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	001	2	6/27/2013	NON-COMPETING CONTINUATION	$175,749


Issue Date FY: 2012 ( Subtotal = $375,271 )
2012	2012	WASHINGTON UNIVERSITY	068552207	SAINT LOUIS	MO	93.395	Cancer Treatment Research	000	1	4/26/2012	NEW	$375,271


Grand Total All Awards = $3,709,956

Sum of Action Amount is $3,709,956;

Grand Total = $3,709,956

Top

All Categories

About

Search

Reports

Data Submission

Award Information

On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49

Award Number: R01CA163764

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer